eligibility_summary
Eligible: ages 3–70 with r/r T‑ALL/LBL, CD7+, ≥5% marrow blasts, adequate organ function (CrCl ≥60, ALT/AST <3×ULN, bilirubin <1.5×ULN/≤1.5 mg/dL), LVEF ≥50%, O2 sat ≥92%, ECOG 0–2, life expectancy >3 mo, consent. Exclude: marrow‑failure syndromes, key cardiac/neuro disease, other malignancy, immune deficiency, active/uncontrolled infections (HIV/HBV/HCV/syphilis), recent anticancer therapy or steroids, live vaccine <4 wks, acute GvHD, product allergy, pregnancy, or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05902845 tests RD13-02 CAR-T cell injection in r/r CD7+ T-ALL/T-LBL. Intervention: RD13-02 is a gene‑modified chimeric antigen receptor T‑cell therapy, single infusion of 2×10^8 CAR+ T cells. Mechanism: patient T cells are engineered to express an anti‑CD7 CAR, CAR binding to CD7 triggers intracellular costimulatory/CD3ζ signaling, activating T cells to release cytokines and kill targets via perforin/granzyme. Targets: CD7 antigen on T‑lineage lymphoblasts (and normal CD7+ T/NK cells), aiming to eliminate CD7+ malignant cells by redirecting cytotoxic T‑cell activity.